カテゴリー： 世界, 医療/バイオ, Market Monitor Global

世界のCAR T細胞ベース薬剤市場予測2023-2029：CD19標的、BCMA標的

【英語タイトル】Drug based on CAR T-Cell Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが出版した調査資料（MMG23LY8481）・商品コード：MMG23LY8481
・発行会社（調査会社）：Market Monitor Global
・発行日：2023年7月
・ページ数：106
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
・産業分野：医薬品＆ヘルスケア
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界のCAR T細胞ベース薬剤市場規模と予測を収録しています。・世界のCAR T細胞ベース薬剤市場：売上、2018年-2023年、2024年-2029年
・世界のCAR T細胞ベース薬剤市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のCAR T細胞ベース薬剤市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「CD19標的」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

CAR T細胞ベース薬剤のグローバル主要企業は、Novartis、 Gilead Sciences、 Bristol-Myers Squibb、 J & J、 JW Therapeutics、 FOSUNKite、 CARsgen Therapeutics (Pipeline)、 CARsgen Therapeutics、 Autolus Therapeutics、 Sorrento Therapeutics、 Mustang Bio、 Bluebird Bio、 Cellectis、 Allogene Therapeutics、 Celyadなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、CAR T細胞ベース薬剤のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界のCAR T細胞ベース薬剤市場：タイプ別、2018年-2023年、2024年-2029年
世界のCAR T細胞ベース薬剤市場：タイプ別市場シェア、2022年
・CD19標的、BCMA標的

世界のCAR T細胞ベース薬剤市場：用途別、2018年-2023年、2024年-2029年
世界のCAR T細胞ベース薬剤市場：用途別市場シェア、2022年
・リンパ腫、多発性骨髄腫

世界のCAR T細胞ベース薬剤市場：地域・国別、2018年-2023年、2024年-2029年
世界のCAR T細胞ベース薬剤市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業におけるCAR T細胞ベース薬剤のグローバル売上、2018年-2023年
・主要企業におけるCAR T細胞ベース薬剤のグローバル売上シェア、2022年
・主要企業におけるCAR T細胞ベース薬剤のグローバル販売量、2018年-2023年
・主要企業におけるCAR T細胞ベース薬剤のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Novartis、 Gilead Sciences、 Bristol-Myers Squibb、 J & J、 JW Therapeutics、 FOSUNKite、 CARsgen Therapeutics (Pipeline)、 CARsgen Therapeutics、 Autolus Therapeutics、 Sorrento Therapeutics、 Mustang Bio、 Bluebird Bio、 Cellectis、 Allogene Therapeutics、 Celyad

*************************************************************

・調査・分析レポートの概要
CAR T細胞ベース薬剤市場の定義
市場セグメント
世界のCAR T細胞ベース薬剤市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のCAR T細胞ベース薬剤市場規模
世界のCAR T細胞ベース薬剤市場規模：2022年 VS 2029年
世界のCAR T細胞ベース薬剤市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのCAR T細胞ベース薬剤の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のCAR T細胞ベース薬剤製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：CD19標的、BCMA標的
CAR T細胞ベース薬剤のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：リンパ腫、多発性骨髄腫
CAR T細胞ベース薬剤の用途別グローバル売上・予測

・地域別市場分析
地域別CAR T細胞ベース薬剤市場規模 2022年と2029年
地域別CAR T細胞ベース薬剤売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Novartis、 Gilead Sciences、 Bristol-Myers Squibb、 J & J、 JW Therapeutics、 FOSUNKite、 CARsgen Therapeutics (Pipeline)、 CARsgen Therapeutics、 Autolus Therapeutics、 Sorrento Therapeutics、 Mustang Bio、 Bluebird Bio、 Cellectis、 Allogene Therapeutics、 Celyad
...

Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.
This report aims to provide a comprehensive presentation of the global market for Drug based on CAR T-Cell, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drug based on CAR T-Cell. This report contains market size and forecasts of Drug based on CAR T-Cell in global, including the following market information:
Global Drug based on CAR T-Cell Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Drug based on CAR T-Cell market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
CD19-targeted Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Drug based on CAR T-Cell include Novartis, Gilead Sciences, Bristol-Myers Squibb, J & J, JW Therapeutics, FOSUNKite, CARsgen Therapeutics (Pipeline), CARsgen Therapeutics and Autolus Therapeutics, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Drug based on CAR T-Cell companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Drug based on CAR T-Cell Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Drug based on CAR T-Cell Market Segment Percentages, by Type, 2022 (%)
CD19-targeted
BCMA-targeted
Global Drug based on CAR T-Cell Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Drug based on CAR T-Cell Market Segment Percentages, by Application, 2022 (%)
Lymphoma
Multiple Myeloma
Global Drug based on CAR T-Cell Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Drug based on CAR T-Cell Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Drug based on CAR T-Cell revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Drug based on CAR T-Cell revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics (Pipeline)
CARsgen Therapeutics
Autolus Therapeutics
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Cellectis
Allogene Therapeutics
Celyad
Outline of Major Chapters:
Chapter 1: Introduces the definition of Drug based on CAR T-Cell, market overview.
Chapter 2: Global Drug based on CAR T-Cell market size in revenue.
Chapter 3: Detailed analysis of Drug based on CAR T-Cell company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drug based on CAR T-Cell in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Drug based on CAR T-Cell Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Drug based on CAR T-Cell Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Drug based on CAR T-Cell Overall Market Size
2.1 Global Drug based on CAR T-Cell Market Size: 2022 VS 2029
2.2 Global Drug based on CAR T-Cell Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Drug based on CAR T-Cell Players in Global Market
3.2 Top Global Drug based on CAR T-Cell Companies Ranked by Revenue
3.3 Global Drug based on CAR T-Cell Revenue by Companies
3.4 Top 3 and Top 5 Drug based on CAR T-Cell Companies in Global Market, by Revenue in 2022
3.5 Global Companies Drug based on CAR T-Cell Product Type
3.6 Tier 1, Tier 2 and Tier 3 Drug based on CAR T-Cell Players in Global Market
3.6.1 List of Global Tier 1 Drug based on CAR T-Cell Companies
3.6.2 List of Global Tier 2 and Tier 3 Drug based on CAR T-Cell Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Drug based on CAR T-Cell Market Size Markets, 2022 & 2029
4.1.2 CD19-targeted
4.1.3 BCMA-targeted
4.2 By Type – Global Drug based on CAR T-Cell Revenue & Forecasts
4.2.1 By Type – Global Drug based on CAR T-Cell Revenue, 2018-2023
4.2.2 By Type – Global Drug based on CAR T-Cell Revenue, 2024-2029
4.2.3 By Type – Global Drug based on CAR T-Cell Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Drug based on CAR T-Cell Market Size, 2022 & 2029
5.1.2 Lymphoma
5.1.3 Multiple Myeloma
5.2 By Application – Global Drug based on CAR T-Cell Revenue & Forecasts
5.2.1 By Application – Global Drug based on CAR T-Cell Revenue, 2018-2023
5.2.2 By Application – Global Drug based on CAR T-Cell Revenue, 2024-2029
5.2.3 By Application – Global Drug based on CAR T-Cell Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Drug based on CAR T-Cell Market Size, 2022 & 2029
6.2 By Region – Global Drug based on CAR T-Cell Revenue & Forecasts
6.2.1 By Region – Global Drug based on CAR T-Cell Revenue, 2018-2023
6.2.2 By Region – Global Drug based on CAR T-Cell Revenue, 2024-2029
6.2.3 By Region – Global Drug based on CAR T-Cell Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Drug based on CAR T-Cell Revenue, 2018-2029
6.3.2 US Drug based on CAR T-Cell Market Size, 2018-2029
6.3.3 Canada Drug based on CAR T-Cell Market Size, 2018-2029
6.3.4 Mexico Drug based on CAR T-Cell Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Drug based on CAR T-Cell Revenue, 2018-2029
6.4.2 Germany Drug based on CAR T-Cell Market Size, 2018-2029
6.4.3 France Drug based on CAR T-Cell Market Size, 2018-2029
6.4.4 U.K. Drug based on CAR T-Cell Market Size, 2018-2029
6.4.5 Italy Drug based on CAR T-Cell Market Size, 2018-2029
6.4.6 Russia Drug based on CAR T-Cell Market Size, 2018-2029
6.4.7 Nordic Countries Drug based on CAR T-Cell Market Size, 2018-2029
6.4.8 Benelux Drug based on CAR T-Cell Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Drug based on CAR T-Cell Revenue, 2018-2029
6.5.2 China Drug based on CAR T-Cell Market Size, 2018-2029
6.5.3 Japan Drug based on CAR T-Cell Market Size, 2018-2029
6.5.4 South Korea Drug based on CAR T-Cell Market Size, 2018-2029
6.5.5 Southeast Asia Drug based on CAR T-Cell Market Size, 2018-2029
6.5.6 India Drug based on CAR T-Cell Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Drug based on CAR T-Cell Revenue, 2018-2029
6.6.2 Brazil Drug based on CAR T-Cell Market Size, 2018-2029
6.6.3 Argentina Drug based on CAR T-Cell Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Drug based on CAR T-Cell Revenue, 2018-2029
6.7.2 Turkey Drug based on CAR T-Cell Market Size, 2018-2029
6.7.3 Israel Drug based on CAR T-Cell Market Size, 2018-2029
6.7.4 Saudi Arabia Drug based on CAR T-Cell Market Size, 2018-2029
6.7.5 UAE Drug based on CAR T-Cell Market Size, 2018-2029
7 Drug based on CAR T-Cell Companies Profiles
7.1 Novartis
7.1.1 Novartis Company Summary
7.1.2 Novartis Business Overview
7.1.3 Novartis Drug based on CAR T-Cell Major Product Offerings
7.1.4 Novartis Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.1.5 Novartis Key News & Latest Developments
7.2 Gilead Sciences
7.2.1 Gilead Sciences Company Summary
7.2.2 Gilead Sciences Business Overview
7.2.3 Gilead Sciences Drug based on CAR T-Cell Major Product Offerings
7.2.4 Gilead Sciences Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.2.5 Gilead Sciences Key News & Latest Developments
7.3 Bristol-Myers Squibb
7.3.1 Bristol-Myers Squibb Company Summary
7.3.2 Bristol-Myers Squibb Business Overview
7.3.3 Bristol-Myers Squibb Drug based on CAR T-Cell Major Product Offerings
7.3.4 Bristol-Myers Squibb Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.3.5 Bristol-Myers Squibb Key News & Latest Developments
7.4 J & J
7.4.1 J & J Company Summary
7.4.2 J & J Business Overview
7.4.3 J & J Drug based on CAR T-Cell Major Product Offerings
7.4.4 J & J Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.4.5 J & J Key News & Latest Developments
7.5 JW Therapeutics
7.5.1 JW Therapeutics Company Summary
7.5.2 JW Therapeutics Business Overview
7.5.3 JW Therapeutics Drug based on CAR T-Cell Major Product Offerings
7.5.4 JW Therapeutics Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.5.5 JW Therapeutics Key News & Latest Developments
7.6 FOSUNKite
7.6.1 FOSUNKite Company Summary
7.6.2 FOSUNKite Business Overview
7.6.3 FOSUNKite Drug based on CAR T-Cell Major Product Offerings
7.6.4 FOSUNKite Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.6.5 FOSUNKite Key News & Latest Developments
7.7 CARsgen Therapeutics (Pipeline)
7.7.1 CARsgen Therapeutics (Pipeline) Company Summary
7.7.2 CARsgen Therapeutics (Pipeline) Business Overview
7.7.3 CARsgen Therapeutics (Pipeline) Drug based on CAR T-Cell Major Product Offerings
7.7.4 CARsgen Therapeutics (Pipeline) Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.7.5 CARsgen Therapeutics (Pipeline) Key News & Latest Developments
7.8 CARsgen Therapeutics
7.8.1 CARsgen Therapeutics Company Summary
7.8.2 CARsgen Therapeutics Business Overview
7.8.3 CARsgen Therapeutics Drug based on CAR T-Cell Major Product Offerings
7.8.4 CARsgen Therapeutics Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.8.5 CARsgen Therapeutics Key News & Latest Developments
7.9 Autolus Therapeutics
7.9.1 Autolus Therapeutics Company Summary
7.9.2 Autolus Therapeutics Business Overview
7.9.3 Autolus Therapeutics Drug based on CAR T-Cell Major Product Offerings
7.9.4 Autolus Therapeutics Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.9.5 Autolus Therapeutics Key News & Latest Developments
7.10 Sorrento Therapeutics
7.10.1 Sorrento Therapeutics Company Summary
7.10.2 Sorrento Therapeutics Business Overview
7.10.3 Sorrento Therapeutics Drug based on CAR T-Cell Major Product Offerings
7.10.4 Sorrento Therapeutics Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.10.5 Sorrento Therapeutics Key News & Latest Developments
7.11 Mustang Bio
7.11.1 Mustang Bio Company Summary
7.11.2 Mustang Bio Business Overview
7.11.3 Mustang Bio Drug based on CAR T-Cell Major Product Offerings
7.11.4 Mustang Bio Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.11.5 Mustang Bio Key News & Latest Developments
7.12 Bluebird Bio
7.12.1 Bluebird Bio Company Summary
7.12.2 Bluebird Bio Business Overview
7.12.3 Bluebird Bio Drug based on CAR T-Cell Major Product Offerings
7.12.4 Bluebird Bio Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.12.5 Bluebird Bio Key News & Latest Developments
7.13 Cellectis
7.13.1 Cellectis Company Summary
7.13.2 Cellectis Business Overview
7.13.3 Cellectis Drug based on CAR T-Cell Major Product Offerings
7.13.4 Cellectis Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.13.5 Cellectis Key News & Latest Developments
7.14 Allogene Therapeutics
7.14.1 Allogene Therapeutics Company Summary
7.14.2 Allogene Therapeutics Business Overview
7.14.3 Allogene Therapeutics Drug based on CAR T-Cell Major Product Offerings
7.14.4 Allogene Therapeutics Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.14.5 Allogene Therapeutics Key News & Latest Developments
7.15 Celyad
7.15.1 Celyad Company Summary
7.15.2 Celyad Business Overview
7.15.3 Celyad Drug based on CAR T-Cell Major Product Offerings
7.15.4 Celyad Drug based on CAR T-Cell Revenue in Global Market (2018-2023)
7.15.5 Celyad Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Drug based on CAR T-Cell Market Opportunities & Trends in Global Market
Table 2. Drug based on CAR T-Cell Market Drivers in Global Market
Table 3. Drug based on CAR T-Cell Market Restraints in Global Market
Table 4. Key Players of Drug based on CAR T-Cell in Global Market
Table 5. Top Drug based on CAR T-Cell Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Drug based on CAR T-Cell Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Drug based on CAR T-Cell Revenue Share by Companies, 2018-2023
Table 8. Global Companies Drug based on CAR T-Cell Product Type
Table 9. List of Global Tier 1 Drug based on CAR T-Cell Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Drug based on CAR T-Cell Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Drug based on CAR T-Cell Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Drug based on CAR T-Cell Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Drug based on CAR T-Cell Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Drug based on CAR T-Cell Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Drug based on CAR T-Cell Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Drug based on CAR T-Cell Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Drug based on CAR T-Cell Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Drug based on CAR T-Cell Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Drug based on CAR T-Cell Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Drug based on CAR T-Cell Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Drug based on CAR T-Cell Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Drug based on CAR T-Cell Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Drug based on CAR T-Cell Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Drug based on CAR T-Cell Revenue, (US$, Mn), 2024-2029
Table 30. Novartis Company Summary
Table 31. Novartis Drug based on CAR T-Cell Product Offerings
Table 32. Novartis Drug based on CAR T-Cell Revenue (US$, Mn) & (2018-2023)
Table 33. Novartis Key News & Latest Developments
Table 34. Gilead Sciences Company Summary
Table 35. Gilead Sciences Drug based on CAR T-Cell Product Offerings
Table 36. Gilead Sciences Drug based on CAR T-Cell Revenue (US$, Mn) & (2018-2023)
Table 37. Gilead Sciences Key News & Latest Developments
Table 38. Bristol-Myers Squibb Company Summary
Table 39. Bristol-Myers Squibb Drug based on CAR T-Cell Product Offerings
Table 40. Bristol-Myers Squibb Drug based on CAR T-Cell Revenue (US$, Mn) & (2018-2023)
Table 41. Bristol-Myers Squibb Key News & Latest Developments
Table 42. J & J Company Summary
Table 43. J & J Drug based on CAR T-Cell Product Offerings
Table 44. J & J Drug based on CAR T-Cell Revenue (US$, Mn) & (2018-2023)
Table 45. J & J Key News & Latest Developments
Table 46. JW Therapeutics Company Summary
Table 47. JW Therapeutics Drug based on CAR T-Cell Product Offerings
Table 48. JW Therapeutics Drug based on CAR T-Cell Revenue (US$, Mn) & (2018-2023)
Table 49. JW Therapeutics Key News & Latest Developments
Table 50. FOSUNKite Company Summary
Table 51. FOSUNKite Drug based on CAR T-Cell Product Offerings
Table 52. FOSUNKite Drug based on CAR T-Cell Revenue (US$, Mn) & (2018-2023)
Table 53. FOSUNKite Key News & Latest Developments
Table 54. CARsgen Therapeutics (Pipeline) Company Summary
Table 55. CARsgen Therapeutics (Pipeline) Drug based on CAR T-Cell Product Offerings
Table 56. CARsgen Therapeutics (Pipeline) Drug based on CAR T-Cell Revenue (US$, Mn) & (2018-2023)
Table 57. CARsgen Therapeutics (Pipeline) Key News & Latest Developments
Table 58. CARsgen Therapeutics Company Summary
Table 59. CARsgen Therapeutics Drug based on CAR T-Cell Product Offerings
Table 60. CARsgen Therapeutics Drug based on CAR T-Cell Revenue (US$, Mn) & (2018-2023)
Table 61. CARsgen Therapeutics Key News & Latest Developments
Table 62. Autolus Therapeutics Company Summary
Table 63. Autolus Therapeutics Drug based on CAR T-Cell Product Offerings
Table 64. Autolus Therapeutics Drug based on CAR T-Cell Revenue (US$, Mn) & (2018-2023)
Table 65. Autolus Therapeutics Key News & Latest Developments
Table 66. Sorrento Therapeutics Company Summary
Table 67. Sorrento Therapeutics Drug based on CAR T-Cell Product Offerings
Table 68. Sorrento Therapeutics Drug based on CAR T-Cell Revenue (US$, Mn) & (2018-2023)
Table 69. Sorrento Therapeutics Key News & Latest Developments
Table 70. Mustang Bio Company Summary
Table 71. Mustang Bio Drug based on CAR T-Cell Product Offerings
Table 72. Mustang Bio Drug based on CAR T-Cell Revenue (US$, Mn) & (2018-2023)
Table 73. Mustang Bio Key News & Latest Developments
Table 74. Bluebird Bio Company Summary
Table 75. Bluebird Bio Drug based on CAR T-Cell Product Offerings
Table 76. Bluebird Bio Drug based on CAR T-Cell Revenue (US$, Mn) & (2018-2023)
Table 77. Bluebird Bio Key News & Latest Developments
Table 78. Cellectis Company Summary
Table 79. Cellectis Drug based on CAR T-Cell Product Offerings
Table 80. Cellectis Drug based on CAR T-Cell Revenue (US$, Mn) & (2018-2023)
Table 81. Cellectis Key News & Latest Developments
Table 82. Allogene Therapeutics Company Summary
Table 83. Allogene Therapeutics Drug based on CAR T-Cell Product Offerings
Table 84. Allogene Therapeutics Drug based on CAR T-Cell Revenue (US$, Mn) & (2018-2023)
Table 85. Allogene Therapeutics Key News & Latest Developments
Table 86. Celyad Company Summary
Table 87. Celyad Drug based on CAR T-Cell Product Offerings
Table 88. Celyad Drug based on CAR T-Cell Revenue (US$, Mn) & (2018-2023)
Table 89. Celyad Key News & Latest Developments
List of Figures
Figure 1. Drug based on CAR T-Cell Segment by Type in 2022
Figure 2. Drug based on CAR T-Cell Segment by Application in 2022
Figure 3. Global Drug based on CAR T-Cell Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Drug based on CAR T-Cell Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Drug based on CAR T-Cell Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Drug based on CAR T-Cell Revenue in 2022
Figure 8. By Type - Global Drug based on CAR T-Cell Revenue Market Share, 2018-2029
Figure 9. By Application - Global Drug based on CAR T-Cell Revenue Market Share, 2018-2029
Figure 10. By Type - Global Drug based on CAR T-Cell Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Drug based on CAR T-Cell Revenue Market Share, 2018-2029
Figure 12. By Application - Global Drug based on CAR T-Cell Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Drug based on CAR T-Cell Revenue Market Share, 2018-2029
Figure 14. By Region - Global Drug based on CAR T-Cell Revenue Market Share, 2018-2029
Figure 15. By Country - North America Drug based on CAR T-Cell Revenue Market Share, 2018-2029
Figure 16. US Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Drug based on CAR T-Cell Revenue Market Share, 2018-2029
Figure 20. Germany Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2029
Figure 21. France Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Drug based on CAR T-Cell Revenue Market Share, 2018-2029
Figure 28. China Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2029
Figure 32. India Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Drug based on CAR T-Cell Revenue Market Share, 2018-2029
Figure 34. Brazil Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Drug based on CAR T-Cell Revenue Market Share, 2018-2029
Figure 37. Turkey Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Drug based on CAR T-Cell Revenue, (US$, Mn), 2018-2029
Figure 41. Novartis Drug based on CAR T-Cell Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Gilead Sciences Drug based on CAR T-Cell Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Bristol-Myers Squibb Drug based on CAR T-Cell Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. J & J Drug based on CAR T-Cell Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. JW Therapeutics Drug based on CAR T-Cell Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. FOSUNKite Drug based on CAR T-Cell Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. CARsgen Therapeutics (Pipeline) Drug based on CAR T-Cell Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. CARsgen Therapeutics Drug based on CAR T-Cell Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Autolus Therapeutics Drug based on CAR T-Cell Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Sorrento Therapeutics Drug based on CAR T-Cell Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Mustang Bio Drug based on CAR T-Cell Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Bluebird Bio Drug based on CAR T-Cell Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Cellectis Drug based on CAR T-Cell Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Allogene Therapeutics Drug based on CAR T-Cell Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Celyad Drug based on CAR T-Cell Revenue Year Over Year Growth (US$, Mn) & (2018-2023)



★調査レポート[世界のCAR T細胞ベース薬剤市場予測2023-2029：CD19標的、BCMA標的] (コード：MMG23LY8481)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のCAR T細胞ベース薬剤市場予測2023-2029：CD19標的、BCMA標的]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のCAR-T細胞治療薬市場予測2023-2029：CD19標的、BCMA標的
  • 世界の慢性疲労症候群治療薬市場予測2023-2029：鎮痛剤・NSAID、抗うつ薬・抗精神病薬、抗菌薬・免疫調節薬
  • 世界の腰痛治療薬市場予測2023-2029：急性用治療薬、慢性用治療薬
  • 世界の高シュウ酸尿症一次治療薬市場予測2023-2029：ALLN-230、DCR-PHXC、ALN-GO1、その他
  • 世界の樹状細胞ワクチン市場予測2023-2029：非標的型、標的型

    • ◆H&Iグローバルリサーチのお客様（例）◆